- UK police seek information on newspaper eavesdropping
- Obama launches big week on economy
- Firm can't fire man for 1.8 cent theft
- What might make the Fed flinch?
- God did not create the universe, says Hawking
- German party mistakenly hands out porn pens to kids
- Guatemala landslides kill dozens, toll seen rising
- Eight policemen dead in Pakistan suicide attack
- Islamist threat to Germany is growing say police
- Europe Factors-Shares set to add to last week's rally
| Report Title | Price |
|---|---|
|
Trading Report for (PFE). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$18.0
|
|
Provider: Pechala's Reports
|
$25.0
|
|
Provider: Wright Reports
|
$169.0
|
|
Provider: Wright Reports
|
$169.0
|
|
Provider: Wright Reports
|
$169.0
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
EU firms pilot Swedish scheme to stop fake drugs
* 25 pharmacies in Stockholm to test data matrix system
* Drug industry aims for eventual Europe-wide scheme
LONDON, Oct 20 (Reuters) - European drugmakers said on Tuesday they were piloting an anti-counterfeit coding system in Sweden in a bid to end the risk of fake medicines entering the supply chain.
Drug companies are increasingly concerned about bogus drugs getting into the legitimate distribution system, potentially posing serious health hazards and undermining the reputation of their products.
The scheme is backed by European Federation of Pharmaceutical Industries and Associations, which hopes it will form the basis of an eventual Europe-wide system.
The new verification system is being tested in conjunction with Swedish pharmaceutical retailer Apoteket and local wholesaler Tamro & Oriola-KD.
Initially, it will be trialled in 25 retail pharmacies in and around Stockholm and will verify more than 100,000 products.
Each pack of medicine will be labelled with a small data matrix -- similar to a bar code -- allowing almost instantaneous verification of the product.
In recent years, counterfeit versions of top-selling drugs such as Pfizer's (PFE.N) Lipitor and Sanofi-Aventis's (SASY.PA) Plavix have been found in the legitimate supply chain.
Pharmaceutical manufacturers say the legal practice of parallel trade -- in which drugs bought in low-priced markets are repackaged and resold in high-price countries -- makes Europe an easy target for counterfeiters. Parallel traders deny the charge. (Reporting by Ben Hirschler; Editing by David Holmes)
